Prostate cancer is the most common malignancy in males other than skin cancer and is the second leading cause of cancer death in men. Prostate cancer growth in most patients is androgen dependent, so that removing androgens (androgen ablation) by orchiectomy or the administration of LHRH agonists is a very effective treatment. Unfortunately, most patients develop androgen-independent (AI) prostate cancer within two years, for which there is no effective treatment. The mechanisms by which tumor cells escape androgen ablation and become androgen-independent are unknown. However, several lines of evidence indicate that mutations in the androgen receptor (AR), which mediates the effects of androgens on prostate cells, may be one important mechanism.
The specific aims of this project are 1) to determine the frequency and spectrum of AR mutations in AI prostate cancer and 2) to determine the functional significance of these mutations. The AR from a series AI prostate cancer patients will be analyzed by reverse transcription- polymerase chain reaction amplification, using involved bone marrow as the primary source of tumor. Mutations will be identified primarily by DNA sequencing of multiple ARs from each patient. The potential functional significance of AR mutations will be assessed by determining their affinity for a series of steroid hormones and their ability to transactivate a reporter gene linked to an androgen responsive element. Studies will also be initiated to identify drugs which can inhibit mutants ARs. The goal will be to establish whether and by what mechanisms AR mutations play a role in the development of AI prostate cancer. If successful, then these mutant ARs may be useful as targets in the development of new drugs for the treatment of prostate cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Biochemical Endocrinology Study Section (BCE)
Program Officer
Berman, Jules J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Wang, Hongyun; Leav, Irwin; Ibaragi, Soichiro et al. (2008) SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res 68:1625-30
Wang, Hongyun; McKnight, Nicole C; Zhang, Tao et al. (2007) SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res 67:528-36
Yuan, Xin; Li, Tong; Wang, Hongyun et al. (2006) Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol 169:682-96
Fu, Maofu; Rao, Mahadev; Wang, Chenguang et al. (2003) Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23:8563-75
Masiello, David; Cheng, Shinta; Bubley, Glenn J et al. (2002) Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 277:26321-6
Cheng, Shinta; Brzostek, Sabrina; Lee, Suzanne R et al. (2002) Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol 16:1492-501
Balk, Steven P (2002) Androgen receptor as a target in androgen-independent prostate cancer. Urology 60:132-8; discussion 138-9
Yuan, X; Lu, M L; Li, T et al. (2001) SRY interacts with and negatively regulates androgen receptor transcriptional activity. J Biol Chem 276:46647-54
Stanbrough, M; Leav, I; Kwan, P W et al. (2001) Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A 98:10823-8
Taplin, M E; Bubley, G J; Ko, Y J et al. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-5

Showing the most recent 10 out of 14 publications